A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer.
Roth S, Wilson KC, Ramsay RG, Mitchell C, Sampurno S, Pham TD, Huei Kong JC, Wong SQ, Heriot AG, Deva S, Burge M, Sverdrup C, Moller AS, Kuryk L, Eriksen JA, Jaderberg M, Zalcberg JR, Michael M.
Roth S, et al. Among authors: wong sq.
Heliyon. 2024 Dec 19;11(1):e41364. doi: 10.1016/j.heliyon.2024.e41364. eCollection 2025 Jan 15.
Heliyon. 2024.
PMID: 39811281
Free PMC article.